Skip to main content

Table 1 Basic characteristics of CVOTs started after 2008 FDA regulation

From: Current perspectives on cardiovascular outcome trials in diabetes

  Study status Drug Drug class Intervention Primary Outcome N Follow-up (years) Start and estimated end date Clinicaltrials.gov ID
SAVOR-TIMI53 Completed Saxagliptin DPP-4 inhibitor Addition of saxagliptin vs. placebo to usual diabetes care CV death, MI, or stroke 18,206 2.1 05.2010–05.2013 NCT01107886
EXAMINE Completed Alogliptin DPP-4 inhibitor Addition of alogliptin vs. placebo to usual diabetes care CV death, MI, or stroke 5380 1.5 10.2009–06.2013 NCT00968708
TECOS Completed Sitagliptin DPP-4 inhibitor Sitagliptin vs. placebo CV death, MI, UA, or stroke 14,724 3 12.2008–03.2015 NCT00790205
ELIXA Completed Lixisenatide GLP-1 inhibitor Lixisenatide vs. placebo CV death, MI, UA, or stroke 6076 2.1 06.2010–02.2015 NCT01147250
EMPA-REG OUTCOME Completed Empagliflozin SGLT-2 inhibitor Empagliflozin 10 mg vs. empagliflozin 25 mg vs. placebo CV death, MI, or stroke 7000 3.1 07.2010–04.2015 NCT01131676
LEADER Completed Liraglutide GLP-1 inhibitor Liraglutide vs. placebo CV death, MI, or stroke 9340 3.8 08.2010–12.2015 NCT01179048
SUSTAIN-6 Completed Semaglutide GLP-1 inhibitor Semaglutide 0.5 mg vs. semaglutide 1.0 mg vs. placebo CV death, MI, or stroke 3299 1.99 02.2013–01.2016 NCT01720446
EXSCEL Ongoing, not recruiting Exenatide GLP-1 inhibitor Exenatide once weekly vs. placebo CV death, MI, or stroke 14,000   06.2010–04.2018 NCT01144338
CAROLINA Ongoing, not recruiting Linagliptin DPP-4 inhibitor Liraglutide vs. placebo CV death, MI, UA, or stroke 6000   10.2010–09.2018 NCT01243424
REWIND Ongoing, not recruiting Dulaglutide GLP-1 inhibitor Dulaglutide vs. placebo CV death, MI, or stroke 9622   07.2011–01.2016 NCT01394952
ITCA650 Ongoing, not recruiting Exenatide in DUROS GLP-1 inhibitor ITCA 650 (exenatide in DUROS) vs. placebo CV death, MI, UA, or stroke 4000   03.2013–07.2018 NCT01455896
DECLARE-TIMI Ongoing, not recruiting Dapagliflozin SGLT-2 inhibitor Dapagliflozin 10 mg vs. placebo CV death, MI, or stroke 17,276   01.2013–04.2019 NCT01730534
CARMELINA Ongoing, not recruiting Linagliptin DPP-4 inhibitor Linagliptin vs. placebo CV death, MI, UA, or stroke 8000   07.2013–01.2018 NCT01897532
DEVOTE Ongoing, not recruiting Insulin degludec Basal insulins Insulin degludec vs. insulin glargine CV death, MI, or stroke 7637   10.2013–09.2016 NCT01959529
MK-3102 Ongoing, not recruiting MK-3102 DPP-4 inhibitor MK-3102 vs. placebo CV death, MI, UA, or stroke 4202   10.2012–12.2020 NCT01703208
Ertugliflozin trial Ongoing, not recruiting Ertugliflozin SGLT-2 inhibitor Ertugliflozin 5 mg vs. ertugliflozin 15 mg vs. placebo CV death, MI, or stroke 3900   11.2013–06.2020 NCT01986881
TOSCA-IT Ongoing, not recruiting Pioglitazone PPAR-γ agonists Pioglitazone vs. sulfonylurea Death, MI, stroke or coronary revascularisation 3371   09.2008–12.2018 NCT00700856
CANVAS Ongoing, not recruiting Canagliflozin SGLT-2 inhibitor Canagliflozin 100 mg vs. canagliflozin 300 mg vs. placebo CV death, MI, UA, or stroke 4418   12.2009–06.2017 NCT01032629